52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Qiagen Builds On Global Collaboration With Amgen For Companion Diagnostic Development In Non-Small Cell Lung Cancer
Qiagen Says Concludes Strategic Alternatives Review
Qiagen And Diasorin Receive FDA Approval For Liaison Quantiferon-TB Gold Plus Test
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Biotechnology & Drugs
Independent Chairman of the Supervisory Board
Interim Chief Executive Officer, Member of the Executive Committee
Managing Director, Chief Financial Officer, Member of the Executive Committee
Senior Vice President, Head of Global Operations, Member of the Executive Committee
Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The following are some of the factors that may move German stocks on Tuesday:
European stocks wrapped up a holiday-thinned week at record highs on Friday as growing hopes that a Sino-U.S. trade deal would be inked soon, as well as the latest dose of upbeat China data supported prospects of an improving global growth.
European shares rose to another record high on Friday, as investors remained optimistic about an improving global economy after a fresh dose of upbeat economic data from China and firming indications of a preliminary U.S.-China trade deal.
The following are some of the factors that may move German stocks on Friday:
Genetic testing firm Qiagen NV <QIA.DE> <QGEN.N> said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.
Genetic testing firm Qiagen NV said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.
German health technology company Siemens Healthineers is not interested in a takeover of Qiagen, the genetic testing company which last month said it would start talks with several potential suitors.
European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector.
A bidding war for Spanish bourse BME and gains in defensive stocks propped up European markets on Monday, although doubts on whether or not the United States will impose tariffs on EU carmakers weighed on shares.
Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.
European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth.
The following are some of the factors that may move German stocks on Monday:
Qiagen NV <QGEN.O> said on Friday it has started reviewing options, including sale, after the genetic testing company received several indications of interest for acquisition, sending its U.S. listed shares up 8.5%.
Qiagen NV said on Friday it has started reviewing options after the healthcare company got several indications of interest for acquisition.
The following bids, mergers, acquisitions and disposals were reported by 2200 GMT on Thursday:
European shares closed lower on Thursday as a warning from German carmaker Daimler and weak economic data from major economies added to concerns about a global slowdown.
The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Thursday:
European shares dipped lower in early trade on Thursday, as a drop in Daimler shares and lackluster economic data from Asia as well as Europe, checked any gains from a handful of positive corporate updates.
The following are some of the factors that may move German stocks on Thursday:
Instruments maker Thermo Fisher Scientific Inc <TMO.N> has approached genetic testing specialist Qiagen NV <QIA.DE> <QGEN.N> about a potential deal, Bloomberg https://www.bloomberg.com/news/articles/2019-11-13/thermo-fisher-said-to-weigh-purchase-of-diagnostics-firm-qiagen...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.